Journal article
LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease
Journal of neuropathology and experimental neurology, v 65(9), pp 866-872
Sep 2006
PMID: 16957580
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
LR11 is an ApoE receptor that is enriched in the brain. We have shown that LR11 is markedly downregulated in patients with sporadic Alzheimer disease (AD). This finding led us to explore whether reduced LR11 expression reflects a primary mechanism of disease or merely a secondary consequence of other AD-associated changes. Therefore, LR11 expression was assessed in a transgenic mouse model of AD and familial AD (FAD) brains. Immunohistochemistry and immunoblotting of LR11 in PS1/APP transgenic and wild-type mice indicated that LR11 levels are not affected by genotype or accumulation of amyloid pathology. LR11 expression was also evaluated based on immunoblotting and LR11 immunostaining intensity in human frontal cortex in controls, sporadic AD, and FAD, including cases with presenilin-1 (PS1) and presenilin-2 (PS2) mutations. Although LR11 was reduced in sporadic AD, there was no difference in protein level or staining intensity between control and FAD cases. The finding that LR11 expression is unaffected in both a mouse model of AD and autosomal-dominant forms of AD suggests that LR11 is not regulated by amyloid accumulation or other AD neuropathologic changes. We hypothesize that LR11 loss may be specific to sporadic AD and influence amyloid pathology through mechanisms independent of substrate-enzyme interactions regulated by FAD mutations.
Metrics
Details
- Title
- LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease
- Creators
- Sara E Dodson - Emory UniversityMarla Gearing - Emory UniversityCarol F Lippa - Drexel UniversityThomas J Montine - University of WashingtonAllan I Levey - Emory UniversityJames J Lah - Emory University
- Publication Details
- Journal of neuropathology and experimental neurology, v 65(9), pp 866-872
- Publisher
- Lippincott
- Grant note
- P50 AG025688-04 / NIA NIH HHS P50 AG025688-02 / NIA NIH HHS P50 AG025688 / NIA NIH HHS AG05136 / NIA NIH HHS R01 AG024214-04 / NIA NIH HHS P50 AG005136 / NIA NIH HHS AG025688 / NIA NIH HHS F31 NS055881-02 / NINDS NIH HHS P50 AG025688-03 / NIA NIH HHS P50 AG025688-01 / NIA NIH HHS AG024214 / NIA NIH HHS P50 AG005136-259003 / NIA NIH HHS R01 AG024214 / NIA NIH HHS
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000241692400004
- Scopus ID
- 2-s2.0-33748536734
- Other Identifier
- 991019312373104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Clinical Neurology
- Neurosciences
- Pathology